Trial Profile
A study evaluating safety and efficacy of Vismodegib for radiation induced multiple basal cell carcinomas of the scalp.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2017
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2017 New trial record